세계의 패혈증 진단 시장 규모는 2023년에 6억 4,448만 달러, 2030년 11억 1,482만 달러에 달하며, 2024-2030년의 예측 기간에 CAGR로 9.60%의 성장이 전망됩니다. 시장은 COVID-19 팬데믹의 유행, 노년 인구의 증가, 결핵 등 세균 감염증의 유행 증가, 첨단 기술을 이용한 패혈증 진단 제품에 대한 규제기관 승인의 급증 등의 다양한 요인에 의해 플러스 성장을 보이고 있습니다. 따라서 시장은 2024-2030년의 예측 기간에 대폭적인 CAGR로의 성장이 전망됩니다.
패혈증 진단 시장 역학
패혈증 진단 시장의 주요 촉진요인 중 하나는 COVID-19 팬데믹의 유행입니다. 2022년 7월 1일에 공표된 세계보건기구(WHO)의 데이터에 따르면 전 세계에서 COVID-19의 증례가 5억 4,522만 6,550건 확인되고 있습니다. 이와 같이 COVID-19는 호흡기에 잘 알려진 영향을 미치며, 희생자의 대부분은 다양한 중증도 폐렴으로 입원을 필요로 하나, 그럼에도 불구하고 대부분의 다른 장기 계통에 영향을 미칠 수 있습니다. 이는 패혈증과 바이러스에 의한 직접적 침습이 혼합되어 있는 것과 일치합니다. 따라서 패혈증 진단은 감염 및 장기 손상의 징후를 확인하기 위해 시도되고 있으며, 이는 패혈증 진단에 대한 수요를 증가시켜 예측 기간(2024-2030년) 동안 전체 패혈증 진단 시장을 촉진할 수 있습니다.
WHO가 2023년 발표한 자료에 따르면 2015-2050년 60세 이상 인구가 12-22%에서 두 배로 증가하며 2050년에는 21억 명에 달할 것으로 추정됩니다. 또한 2030년 전 세계 인구 6명 중 1명은 60세 이상이 될 것입니다. 위의 데이터에 따르면 80세 이상 인구는 2020-2050년 사이 3배 증가하여 4억 2,600만 명에 달할 것으로 예측됩니다. 또한 연령이 높아질수록 면역 체계가 약해져 감염에 걸릴 확률이 높아져 패혈증 진단에 대한 수요가 증가할 수 있습니다. 따라서 노인 인구 증가는 패혈증 진단에 대한 수요를 증가시켜 예측 기간(2024-2030년) 동안 전체 패혈증 진단 시장을 촉진하는 요인이 될 것입니다.
따라서 앞서 언급한 요인들은 패혈증 진단에 대한 수요를 증가시켜 예측 기간(2024-2030년) 동안 전체 패혈증 진단 시장의 성장을 가속할 수 있습니다.
그러나 높은 패혈증 치료 비용과 패혈증에 대한 인식 및 지식 부족은 세계 패혈증 진단 시장의 성장을 저해할 수 있습니다.
진행 중인 COVID-19 팬데믹은 패혈증 진단 시장에 다소 긍정적인 영향을 미치고 있으며, Global Sepsis Alliance에 따르면 SARS-CoV-2는 패혈증을 유발한다고 합니다. 이는 바이러스성 패혈증이 COVID-19 환자의 가장 흔한 합병증으로 사망률 증가로 이어진다는 최근 연구에 의해 지원되고 있으며, COVID-19는 환자의 호흡기에 영향을 미치기 때문에 대부분의 환자가 다양한 중증도의 폐렴으로 입원해야 하지만, 기타 다른 대부분의 환자들은 그럼에도 불구하고, 다른 대부분의 장기 시스템도 영향을 받을 수 있습니다. 이는 패혈증과 바이러스에 의한 직접적인 침습이 혼합되어 있는 것과 일치합니다. 따라서 COVID-19 확진자 급증은 패혈증 진단에 대한 수요를 증가시키고, COVID-19 확진자 증가는 패혈증 진단에 사용되는 툴, 시약 및 검사 키트에 대한 수요를 증가시켜 전체 패혈증 진단 시장의 급격한 성장을 가져올 것으로 예상됩니다.
패혈증 진단 시장 부문별 분석
패혈증 진단 시장의 제품 유형 부문에서는 기기 및 키트 부문이 2024-2030년의 예측 기간 중 큰 성장세를 보일 것으로 예상됩니다. 예를 들어 혈액 배양 식별 패널(BCID)은 혈류 감염과 관련된 병원체 및 항생제 내성 유전자를 신속하고 정확하게 식별할 수 있습니다. 혈류 감염과 관련된 3가지 항생제 내성 유전자뿐만 아니라 다양한 병원체(24종)를 검사할 수 있습니다. 또한 약 1시간, 단 2분 정도의 짧은 시간 동안 단 한 번의 검사로 혈액배양 양성 10건 중 9건의 감염을 확인할 수 있습니다. 이러한 BCID와 관련된 장점은 시장에서 기기 및 키트에 대한 수요를 증가시켜 예측 기간 중 세계 패혈증 진단 시장의 전체 성장을 가속할 수 있습니다.
세계의 패혈증 진단 시장에 대해 조사분석했으며, 시장 규모와 예측, 촉진요인과 과제, 기업과 제품 개요 등을 제공하고 있습니다.
Sepsis Diagnostics Market By Techniques Type (Immunoassay, Molecular Diagnosis, Microbiology, Flow Cytometry, And Others), By Test Type (Laboratory Testing And Point Of Care Testing), By Product Type (Assays & Reagents And Instruments & Kits), By Pathogen (Bacterial, Fungal, And Others), By End-User (Hospitals, Pathology Laboratories, And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of covid-19 pandemic and a rise in the geriatric population
The global sepsis diagnostics market was valued at USD 644.48 million in 2023, growing at a CAGR of 9.60% during the forecast period from 2024 to 2030 to reach USD 1114.82 million by 2030. The sepsis diagnostics market is witnessing positive growth owing to various factors such as the increasing prevalence of the COVID-19 pandemic, a rise in the geriatric population, the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for the technologically advanced sepsis diagnostics products. Therefore, the market for sepsis diagnostics is estimated to grow at a significant CAGR during the forecast period from 2024 to 2030.
Sepsis Diagnostics Market Dynamics:
One of the main drivers of the sepsis diagnostics market is the increasing prevalence of the COVID-19 pandemic. According to the World Health Organization (WHO) data published on 1 July 2022, there have been 545,226,550 confirmed cases of COVID-19 all over the world. Thus, COVID-19 has well-known effects on the respiratory system, with the majority of victims requiring hospitalization for pneumonia of various severity, nonetheless, almost all other organ systems can be impacted. This is consistent with a mix of sepsis and direct viral invasion. Therefore, sepsis diagnosis is attempted to verify or check the signs of any infection or organ damage with the disease, this can boost the demand for sepsis diagnostics, which could surge the sepsis diagnostics overall market forward during the forecast period (2024-2030).
Moreover, another key factor that is responsible for the growth of sepsis diagnostics is the rise in the geriatric population, as per the data published by the WHO in the year 2023, it was estimated that between the years 2015-2050 the number of citizens who aged 60 years and above will get doubled from 12-22% and will reach 2.1 billion by the year 2050. Adding to it, by the year 2030, one out of every six individuals worldwide will age 60 years or more. As per the above-mentioned data, the number of citizens aged 80 years or over is expected to get triple between the years 2020 and 2050 & will reach 426 million population. Furthermore, as age increases chances of suffering from infections also increase due to weakening immune systems which can boost the demand for sepsis diagnosis. Therefore, the rising geriatric population increases the demand for sepsis diagnostics, this surge the sepsis diagnostics overall market forward during the forecast period (2024-2030).
Therefore, the aforementioned factors could increase the demand for sepsis diagnostics, which can surge the growth of the overall sepsis diagnostics market during the forecast period from 2024-2030.
However, the high cost of sepsis treatment and the lack of awareness & knowledge about sepsis can hamper the global sepsis diagnostics market growth.
The ongoing COVID-19 epidemic has slightly positively impacted the sepsis diagnostics market. According to the Global Sepsis Alliance, SARS-CoV-2 causes sepsis. This is reinforced by a recent study, which found that viral sepsis is the most common complication in COVID-19 patients and is linked to increased mortality. Since, COVID-19 affects the patient's respiratory system, with the majority of patients requiring hospitalization for pneumonia of various severity, nonetheless, almost all other organ systems can be impacted. This is consistent with a mix of sepsis and direct viral invasion. Thus, the surge in COVID-19 pandemic cases boosted the demand for sepsis diagnostics, and the further increase in the COVID-19 cases is expected to increase the demand for tools, reagents, and test kits for sepsis detection, resulting in the surge in sepsis diagnostics overall market.
Sepsis Diagnostics Market Segment Analysis:
Sepsis Diagnostics Market by Techniques Type (Immunoassay, Molecular Diagnosis, Microbiology, Flow Cytometry, and Others), Test Type (Laboratory Testing and Point Of Care Testing), Product Type (Assays & Reagents, Instruments & Kits), Pathogen (Bacterial, Fungal, and Others), End-User (Hospitals, Pathology Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the sepsis diagnostics market, the instruments & kits segment is expected to show significant growth during the forecast from 2024-2030. For instance, the Blood Culture Identification Panel (BCID), allows for the quick as well as precise identification of pathogens and antibiotic resistance genes associated with bloodstream infections. It looks for a wide range of pathogens (24) as well as 3 antibiotic resistance genes linked to bloodstream infections. Moreover, in roughly an hour, with only 2 minutes of hands-on work, it helps to identify infections in 9 out of 10 positive blood cultures with just one test. Thus, the benefits associated with the BCID, uplift the instruments & kits demand in the market, which could drive the growth of the overall global sepsis diagnostics market during the forecast period.
Furthermore, the developments in sepsis diagnostics products, are also expected to drive the market growth for it. For instance, in May 2022, BioMerieux, a global pioneer in-vitro diagnostics player, gained clearance from Health Canada for its BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. In comparison to the original BIOFIRE® BCID Panel, the BIOFIRE® BCID2 Panel for quick molecular diagnosis of bloodstream infection contains numerous more pathogens, an extended list of antibiotic resistance genes, and many altered targets.
Hence, due to the interplay of the factors mentioned above, the sepsis diagnostics demand increases in the market, which can drive the growth of the global sepsis diagnostics market during the forecast period.
North America is expected to dominate the overall Sepsis Diagnostics Market:
Among all the regions, North America is expected to dominate the global sepsis diagnostics market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. Factors such as the increasing prevalence of bacterial infections such as tuberculosis and the surge in the regulatory approvals for technologically advanced sepsis diagnostics products are expected to increase the demand for sepsis diagnostics in the North America market.
According to the Centers for Disease Control and Prevention (CDC) published data in the year 2023, in the year 2023, the number of Tuberculosis (TB) cases in the United States was 7,860 which is equivalent to 2.4 per 100,000 persons. Thus, tuberculosis could lead to sepsis shock, which can result in improved demand for sepsis diagnostics, contributing to the conductive growth for sepsis diagnostics overall market forecast from 2024-2030.
Moreover, the surge in regulatory approvals for technologically advanced sepsis diagnostics products can boost the sepsis diagnostics overall market in the region. For instance, in February 2022, Noninvasix, which is expected to be the first company to non-invasively monitor central venous oxygenation announced that its LIVOx(TM) Central Venous Oxygenation Monitor has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for non-invasive, real-time, continuous or spot monitoring of central venous oxygen saturation (ScvO2) in adults at risk of septic shock in the United States.
Therefore, with the interplay of the factors mentioned above, there will be high demand for sepsis diagnostics, which would provide a conducive growth environment for the North American region in the sepsis diagnostics market.
Sepsis Diagnostics Market Key Players:
Some of the key market players operating in the sepsis diagnostics market include BD, Cytovale(TM) Inc, Thermo Fisher Scientific Inc, Abbott, F. Hoffmann-La Roche Ltd, bioMerieux SA, Danaher, T2 Biosystems Inc, Luminex Corporation, Bruker, Immunexpress Inc, Axis-Shield Diagnostics Ltd, Quidel Corporation, Siemens Healthcare Private Limited, EKF Diagnostics Holdings plc, Seegene Inc, Boditech Med Inc, Alifax S.r.l. Italy, Koninklijke Philips N.V, Response Biomedical Corp, and others.
Recent Developmental Activities in the Sepsis Diagnostics:
In January 2022, Pathogenomix, a next-generation sequencing, pathogen diagnostic company, was granted US Food and Drug Administration (FDA) Breakthrough Device Designation for its Patho-Seq assay. The assay is designed for the quick detection and identification of hundreds of clinically important bacteria for a wide range of clinical diseases and sample types, including sepsis from whole blood samples and bacterial meningitis from Cerebrospinal Fluid (CSF).
In November 2022, Immunexpress Inc, a molecular diagnostic company focusing on improving outcomes for suspected sepsis patients, announced that SeptiCyte RAPID has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). In hospitalized patients suspected of sepsis, the approved test helps to distinguish sepsis from infection-free systemic inflammation.
In March 2020, Immunexpress, Inc., a molecular diagnostics company focusing on improving outcomes for patients with suspected sepsis, announced that SeptiCyte® RAPID, their host response technology, has achieved CE Marking. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis Idylla platform to provide actionable data in less than an hour, which allows doctors to make better patient care decisions. SeptiCyte® RAPID is a gene expression test that quantifies the relative expression levels of host response genes extracted from whole blood collected in the PAXgene® Blood RNA Tube using reverse transcription-polymerase chain reaction (PCR).
Key Takeaways from the Sepsis Diagnostics Market Report Study
Target Audience who can be benefited from this Sepsis Diagnostics Market Report Study
Frequently Asked Questions for Sepsis Diagnostics:
Sepsis diagnostics includes instruments, lab tests, various technologies, and others, which are used to diagnose sepsis by checking signs of infection or organ damage within the patient.
The global sepsis diagnostics market was valued at USD 644.48 million in 2023, growing at a CAGR of 9.60% during the forecast period from 2024 to 2030 to reach USD 1114.82 million by 2030.
The sepsis diagnostics market is witnessing positive market growth owing to the factors such as the increasing prevalence of the COVID-19 pandemic, a rise in the geriatric population, the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for the technologically advanced sepsis diagnostics products
Some of the key market players operating in the Sepsis diagnostics market include BD, Cytovale(TM) Inc, Thermo Fisher Scientific Inc, Abbott, F. Hoffmann-La Roche Ltd, bioMerieux SA, Danaher, T2 Biosystems Inc, Luminex Corporation, Bruker, Immunexpress Inc, Axis-Shield Diagnostics Ltd, Quidel Corporation, Siemens Healthcare Private Limited, EKF Diagnostics Holdings plc, Seegene Inc, Boditech Med Inc, Alifax S.r.l. Italy, Koninklijke Philips N.V, Response Biomedical Corp, and others.
North America is expected to dominate the global sepsis diagnostics market. Factors contributing to the growth are the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for technologically advanced sepsis diagnostics products contributes to the growth of the sepsis diagnostics market in the North America region.